@SammithecatVi @GingBear3 @millenium_mahu You were worried about it being an old article, you could do another search and quickly find other studies, even a meta study if you like! https://t.co/BTdaNvN4c7

@JetstreamHohlin https://t.co/H5ojBpSxkk

@tochka_luvsu Спикер утверждал что мрут именно от побочек ХРТ. Это было актуально, лет 20 назад когда все повально юзали ЭЭ, только вот от него отказались трансфем давно (и кстати в РФ те же цисженщины используют его как КОК сильно рискуя при том) https:/

@ekat_t59 https://t.co/H5ojBpSxkk

@lisaquestions @EmRoseDeLeon @gayannabeth From 2019: https://t.co/0iS5bF7uvw Latest data shows no increased clot risk with transdermal estradiol. Oral estradiol is the riskiest method.

@orellanin @bonepuncher @NireBryce @maeveynot Ophelia is right. The issue with saying transdermal is definitely lower risk is the dosages studied are non-equivalent. With modern regimens, risk is likely less than combination oral contraceptives are in AFAB

@LindnerVera @YollyRolly @DrKarlynB @teaandabikkie It is insincere how the absence of proper care (that we've been trying to tell doctors to improve) is directly weaponized against us, to push a narrative to stop gender affirming care altogether. But you a

@08Juan80 @keffals Blood clots don't cause deaths. Uhuh. I see American education at work here. https://t.co/BlG8SNAbII

@catshit22 @JLCederblom @highprogressive And your studies don't go into how many begin treatment then stop going. I've conceded that the affects aren't as bad as I though but there absolutely are bad affects, https://t.co/aJsZQ5vNhC

Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy https://t.co/XwWtrQF761

@brennasaid @rustedbelts There have been several review papers in the last couple of years calling for better controlled studies, ex https://t.co/DyUHqGfiF2 https://t.co/643l8behdF https://t.co/U4B4lCHg0N https://t.co/zm1ONiJZbO https://t.co/22Z3uePQfV

RT @MechaniVal: @feline_charm @Andidraws1 @brynismyname @itsjacksonbbz Find the study that this one is referencing here: https://t.co/8wiEg…

@feline_charm @Andidraws1 @brynismyname @itsjacksonbbz Find the study that this one is referencing here: https://t.co/8wiEgvuFbw https://t.co/viFLV15rw7

@brynismyname She also seems to be suggesting there's no data on trans women specifically, that it's all on cis women? Well then, here you go: https://t.co/8wiEgvuFbw https://t.co/8gAy3O5FNW

@shaedygirl @autogynamelia This paper on blood clots is good. It’s important to note that oral estradiol is also bioidentical and the SOC is to only prescribe bioidentical : https://t.co/9tUpQebrYQ

RT @deviantgauge: @cassesque @NicolaJayneHod1 @Valentrans_XO @NICEComms The blood clot risk is poorly studied in trans women, but likely le…

@cassesque @NicolaJayneHod1 @Valentrans_XO @NICEComms The blood clot risk is poorly studied in trans women, but likely less than OCPs in cis women where we avoid ethinyl estradiol and use micronized progesterone and not synthetic progestins. https://t.co/9

@maxima_8 @spompfel https://t.co/GGj4ZDkh1q "the data suggest that the route of hormone administration,[...]and comorbidities all affect estrogen’s link with VTE. >>>

E2 clot (VTE) risk is especially low when using transdermal estrogen and high when using ethinyl estradiol (so don't use that!): https://t.co/IEaMsuQJlE 2.3 VTE per 1000 person-years (but risk advances with age) compared to 1.0-1.8 in general population:

This is precisely why intersectionality in medicine is of profound importance. Here's to hoping that trans women receive better care, which is only possible when there are no biases attached. https://t.co/xgsAFmoKHH